-
Pricing per bottle is $695.65! Lilly AD New Drug Approved for Market, Encountering Strong Competitors with Lencamab
21st Century Business Herald reporter Han Liming reports from Shanghai On July 2nd local time, Lilly (NYSE: LLY) announced that Kisunla (donanemab, 350 mg/20 mL) has been approved by the US FDA for t ... -
Eli Lilly AD new drug approved for market launch, lencamab meets strong competitors
On July 2nd local time, Lilly (NYSE: LLY) announced that Kisunla (donanemab, 350mg/20mL) has been approved by the US FDA for the treatment of early-stage symptoms of Alzheimer's disease (AD), includi ... -
The Class 1 new drug introduced by Anjin with over 1 billion US dollars has been approved for clinical use
New Beijing News (Reporter Zhang Zhaohui) On September 4th, the official website of the National Medical Products Administration announced that a new clinical application for Amgen's Class 1 new drug ... -
AbbVie Dual Anti Cancer New Drug Declares for Market in China
On November 6th, the latest announcement on the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration stated that AbbVie's application for the launc ...